CZC 54252 hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: CZC 54252 hydrochloride
• 英文别名: N-[2-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]phenyl]methanesulfonamide;hydrochloride
• 化学式: C22H26Cl2N6O4S
• 分子量: 541.4
• InChiKey: KWCBHUPLQMUKAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.26
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• Treatment or prevention of an intestinal disease or disorder
  申请人：The United States of America, as represented by the Secretary, Department of Health & Human Services

  公开号：US10058559B2

  公开（公告）日：2018-08-28

  Disclosed are methods of treating or preventing an intestinal disease or disorder comprising administering to a subject a modulator of leucine rich repeat kinase 2 (LRRK2) in an amount effective to treat or prevent an intestinal disease or disorder and methods of determining the susceptibility or risk of a subject to develop an intestinal disease.

  所公开的是治疗或预防肠道疾病或紊乱的方法，包括向受试者施用有效量的富亮氨酸重复激酶 2 (LRRK2) 调节剂以治疗或预防肠道疾病或紊乱，以及确定受试者患肠道疾病的易感性或风险的方法。
• TREATMENT OR PREVENTION OF AN INTESTINAL DISEASE OR DISORDER
  申请人：The United States of America, as represented by the Secretary, Department of Health & Human Servic

  公开号：US20170079987A1

  公开（公告）日：2017-03-23

  Disclosed are methods of treating or preventing an intestinal disease or disorder comprising administering to a subject a modulator of leucine rich repeat kinase 2 (LRRK2) in an amount effective to treat or prevent an intestinal disease or disorder and methods of determining the susceptibility or risk of a subject to develop an intestinal disease.
• [EN] TREATMENT OR PREVENTION OF AN INTESTINAL DISEASE OR DISORDER<br/>[FR] TRAITEMENT OU PRÉVENTION D'UNE MALADIE OU D'UN TROUBLE INTESTINAL
  申请人：US OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENTOF HEALTH & HUMAN SERVICES

  公开号：WO2015176010A1

  公开（公告）日：2015-11-19

  Disclosed are methods of treating or preventing an intestinal disease or disorder comprising administering to a subject a modulator of leucine rich repeat kinase 2 (LRRK2) in an amount effective to treat or prevent an intestinal disease or disorder and methods of determining the susceptibility or risk of a subject to develop an intestinal disease.